Clinical trials: Behavioral
Behavioral and Psychiatric Symptoms of Dementia, Insomnia
Implementation of a Pharmacist-Driven Antipsychotic Deprescribing Initiative in the PACE Setting: A Pilot Study
The aim of this pilot study is to determine the feasibility of implementing an antipsychotic deprescribing initiative that is driven by pharmacists working collaboratively with the Program of All-inclusive Care for the Elderly…
- Trial name
- NCT04288193
- Testing
- Recommendation to Deprescribe
- Where
- United States
- Sponsor
- Tabula Rasa HealthCare
Frontotemporal Dementia, Behavioral Variant Frontotemporal Dementia
Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)
The objectives of the study are to; (1) estimate the change in disease -related cognitive decline over 1 year on a battery of cognitive tests administered to participants with early-stage symptomatic Behavioral Variant…
- Trial name
- FORWARD (NCT03088956)
- Testing
- Assessments
- Where
- 12 sites in United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Biogen
Behavioral and Psychiatric Symptoms of Dementia
The Use of Antipsychotics in the Program of All-inclusive Care for the Elderly (PACE)
The aim of this study is to retrospectively evaluate and describe the use of antipsychotics among participants enrolled in the Program of All-inclusive Care for the Elderly (PACE), a community-based practice setting.
- Trial name
- NCT03692182
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Tabula Rasa HealthCare
Integrating Behavioral Health
Web Platform to Integrate Behavioral Health
Under this Small Business Innovation Research (SBIR) Phase II project, Research Topic 155, the Contractor will create an integrated multi-module system of web software tools to aid in behavioral health screening, prevention…
- Trial name
- NCT03351374
- Testing
- Software
- Where
- 2 sites in United States
- Volunteers
- 16,000 people, healthy volunteers welcome
- Sponsor
- Medical Decision Logic, Inc.
Behavioral and Psychiatric Symptoms of Dementia
Feru-guard for Behavioral Symptoms in Dementia
This is designed as a randomized, double-blind, placebo-controlled clinical trial with a 12 week intervention period. Seventy participants with a diagnosis of AD, vascular, and mixed dementia with at least 3 behavioral symptoms…
- Trial name
- NCT03451760
- Testing
- Feru-guard 100M
- Volunteers
- 70 people
- Sponsor
- Glovia Co., Ltd.
Behavioral Health With Medical Comorbidities
Dashboards for Clinician Monitoring of Patients Through a Mobile Sensing Platform
The purpose of this study is to determine whether the use of a mobile sensing platform in a primary care setting has an effect on provider workflows, patient outcomes, patient engagement, patient self-help behavior, health…
- Trial name
- NCT02167373
- Testing
- Cogito Companion Intervention, mobile phone application
- Where
- United States
- Volunteers
- 171 people
- Sponsor
- Cogito Health Inc
Huntington's Disease
Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021
This study is a 12 month open label extension study of PF-02545920 20 mg dosed BID following study A8241021 in subjects with HD. Primary endpoints will be to assess long-term safety and tolerability of 20 mg BID of PF-02545920.
- Trial name
- NCT02342548
- Testing
- 20 mg BID of PF-02545920
- Where
- 50 sites in United States, Canada and 3 more
- Volunteers
- 188 people
- Sponsor
- Pfizer
Behavioral Variant Frontotemporal Dementia (bvFTD)
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
The purpose of this study is to demonstrate the safety and efficacy of TRx0237 in the treatment of patients with behavioral variant frontotemporal dementia (bvFTD).
- Trial name
- NCT01626378
- Testing
- TRx0237
- Where
- 67 sites in United States, Australia and 10 more
- Volunteers
- 220 people
- Sponsor
- TauRx Therapeutics Ltd
Huntington's Disease
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
This study is a 26 week, randomized, parallel group, double blind comparison of PF-02545920 5 mg, PF-02545920 20 mg, and placebo dosed BID in the treatment of motor impairment of subjects with Huntington's Disease.
- Trial name
- NCT02197130
- Testing
- PF-02545920
- Where
- 57 sites in United States, Canada and 3 more
- Volunteers
- 272 people
- Sponsor
- Pfizer
Behavioral Measures of Tolerance
Nutritive Effects of Prebiotics on Early Postnatal Behavioral Measures of Tolerance
The study is intended to measure infant comfort, behavior, and sleep when consuming study formula with prebiotics compared to infants who consume a study formula without the prebiotics.
- Trial name
- NCT02118935
- Testing
- Previously marketed cow's mlik-based infant formula, Marketed cow's milk-based infant formula with prebiotics
- Where
- 7 sites in United States
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Mead Johnson Nutrition
Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
This is a 10-week study with bifeprunox and placebo in elderly subjects with psychosis and behavioral disturbances associated with dementia of the alzheimer's type.
- Trial name
- NCT00160147
- Testing
- bifeprunox
- Where
- 51 sites in United States, Czechia and 3 more
- Volunteers
- 60 people
- Sponsor
- Solvay Pharmaceuticals
Dementia, Alzheimer Disease
Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine
The main objective of this non-interventional study was to document the long-term application of galantamine and nootropics (memory enhancing drugs) over a period of 1 year under conditions of daily routine.
- Conditions
- Dementia, Alzheimer Disease, Dementia, Vascular
- Trial name
- NCT01009476
- Testing
- Galantamine, Nootropics (ginkgo biloba, nicergoline, piracetam, or others)
- Volunteers
- 1,134 people
- Sponsor
- Janssen-Cilag G.m.b.H
Major Depressive Disorder
Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
To evaluate the long-term safety and tolerability of flexible doses, 15 and 20 mg/day, of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD)
- Trial name
- NCT01323478
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 71 people
- Sponsor
- H. Lundbeck A/S
Dementia, Alzheimer Disease
Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study
The purpose of this study is to assess the effectiveness and safety of galantamine hydrobromide treatment in patients with severe Alzheimer's disease.
- Trial name
- NCT00216593
- Testing
- galantamine hydrobromide
- Volunteers
- 415 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Dementia
Study of Depakote for Behavioral and Psychological Symptoms in Dementia
This prospective, naturalistic, open label study will test the hypothesis that Depakote is correlated with a reduction in elevated Cohen-Mansfield Agitation Index (CMAI) verbal and physical agitation and aggression scales over a…
- Trial name
- NCT00197834
- Testing
- Depakote
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Hearthstone Alzheimer Care